(CercleFinance.com) – OSE Immunotherapeutics announces that the United States Patent and Trademark Office (USPTO) has granted a first agreement to grant a patent relating to OSE-279, an anti-PD1 monoclonal antibody, and its use in the treatment of cancer.
‘We are very pleased with this first agreement to grant an OSE-279 patent in a major territory. This reinforces both the intellectual property of the product and its place in our portfolio of immunotherapy with the potential to transform standard anti-PD1 treatments in difficult-to-treat cancers. We look forward to advancing the development of OSE-279 with a phase 1 clinical trial scheduled to start in 2022,” commented Dominique Costantini, CEO of OSE Immunotherapeutics.